



Novel Biomarkers in the Diagnostics of Cancer

Guest Editors:

Prof. Dr. Daniela Calina

Department of Clinical
Pharmacy, University of Medicine
and Pharmacy of Craiova, 200349
Craiova, Romania

Dr. Luca Falzone

Department of Biomedical and
Biotechnological Sciences,
University of Catania, Catania,
Italy

Deadline for manuscript
submissions:

15 October 2024

Message from the Guest Editors

Dear Colleagues,

This Special Issue aims to serve as a comprehensive platform for the dissemination of the latest research and advancements in the identification and validation of novel cancer biomarkers. We aim to explore not only the molecular intricacies of these markers but also their clinical applications and potential to shape personalized therapeutic strategies.

Specific areas of focus include, but are not limited to: Novel genetic, epigenetic, proteomic, and metabolic markers; Technological advancements in biomarker discovery; Bioinformatics approaches in data mining for potential biomarkers; Clinical utility and validation studies; Implications for personalized medicine and therapy adjustments based on biomarker profiles.

We intend for this Special Issue to bring together a multidisciplinary cohort of researchers, clinicians, and scholars, shedding light on the future of personalized oncology through the lens of biomarker discovery.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA

2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)